

REMARKS/ARGUMENTS

(1)

Applicants note with appreciation that the Examiner has entered the amendment and response filed on March 15, 2007.

Applicants cancel claims 174-175. Claims 109-116, 118-128, 130-140, 143-173, and 176-177 are pending.

(2)

Applicants note with appreciation that the Examiner has withdrawn the rejection of claims 109, 111, 112, 117, 119, 121, 122-124, 129, 131, 133-136, 141 and 143 under 35 U.S.C. § 112, Second Paragraph for the term “comprising” in view of the amendment.

(3)

a) “M” and “E or Z”

Applicants note with appreciation that the Examiner has withdrawn the rejection of claims 109, 112, 121, 124, 133 and 136 under 35 U.S.C. § 112, Second Paragraph for the scope of “M” and for “E or Z” in view of the amendments.

b) “substituent that is convertible *in vivo* to hydrogen”

The Examiner rejected claims 109, 121, and 133 based on new matter for the insertion of “or a substituent that is convertible *in vivo* to hydrogen” into the definition of R₁₄ in claims 109, 121 and 133. The Examiner also rejected claims 112, 124 and 136 for not explicitly naming the members of claims 109, 121, and 133, respectively, that can be converted to hydrogen *in vivo*.

Applicants amend claims 109, 121, and 133 to remove the recitation and respectfully request the Examiner to withdraw the rejections of the claims based on new matter.

Applicants amend claims 112, 124 and 136 to remove “substituent that is convertible *in vivo* to hydrogen” from the definition of R₁₄.

As a result of the amendments, claims 112, 124 and 136 properly depend from claims 109, 121 and 133, respectively and the scope of R₁₄ is clear. Accordingly, this rejection may be withdrawn. Applicants reserve the rights to pursue other members of R₁₄ in claims 109, 121 and

133 as originally filed that can be converted to hydrogen *in vivo* in later filed applications.

(4)

The Examiner maintains the rejection of claims 109 and 121 under 35 U.S.C. § 112, First Paragraph, for allegedly failing to comply with the enablement requirement for the scope of L other than C2-C10. Applicants provided examples in Applicants' Exhibits A-D in response to the previous office action that people skilled in the art would have known to select the linker among those available. The Examiner alleges that none of the recited material indicates any biological activity nor any support of an art recognized Markush variation as the exemplified C2-C10 compounds as histone deacetylase inhibiting activity. The Examiner asserts that the mere provision of the "language" does not constitute enablement.

Applicants disagree with the Examiner's assessment of the examples previously provided by Applicants. However, in the interest of advancing prosecution of the present application, Applicants amend claims 109 and 121 to limit the atoms of L to carbon atoms. Applicants believe the amendment overcomes the rejection of claims 109 and 121 under 35 U.S.C. § 112, First Paragraph, and respectfully request the Examiner to withdraw the rejection.

(5)

Applicants note with appreciation that the Examiner has withdrawn the rejection of claims 109-112, 115, 121-124 under 35 U.S.C. §103(a) as being unpatentable over Vourloumis et al. Tetrahedron Lett. ("Vourloumis") in view of CA139:133505.

(6)

The Examiner provisionally rejects claims 109-116, 118-128, 130-140, 143, and 144-177 on the ground of nonstatutory obviousness-type double patenting as being unpatentable over the pending claims of copending Application No. 10/803,575. The Examiner has suggested that a timely filed terminal disclaimer may be used to overcome the rejection.

Applicants note that the conflicting Application No. 10/803,575 is commonly owned with the current application, and Applicants can provide a terminal disclaimer to overcome the rejection. However, Applicants respectfully request that the Examiner holds the rejection in abeyance until allowable and overlapping subject matters have been identified. Applicants further request that the Examiner notifies the undersigned by telephone then, and Applicants will

promptly submit a terminal disclaimer to obviate the rejection.


CONCLUSION

Applicants earnestly believe that they are entitled to letters patent, and respectfully solicit the Examiner to expedite prosecution of this patent application to issuance. Should the Examiner have any questions, the Examiner is encouraged to telephone the undersigned.

Respectfully submitted,

Dated: August 07, 2007

By:



C. Amy Smith, Reg. No. 42,931

Customer No. 32793
Takeda San Diego, Inc.
10410 Science Center Drive
San Diego, CA 92121
Telephone: (858) 622-8528
Facsimile: (858) 550-0992